Abstract. The 1995 Hyogc-ken Nanbu earthquake (Kobe earthquake; M7.2) occurred on January 17, 1995. A temporary aftershock observation was carried out by the Geophysical Research Group Organized by Universities for Prediction Seismology in 1995 from October 1995 to January 1996. A dense seismic network was deployed in and around the aftershock region, and some seismic stations were set directly on the active fault traces. We analyze the S wave splitting in and around the aftershock region of the Hyogo-ken Nanbu earthquake. We detect a spatial variation of S wave splitting which can be related to crack orientations in an area where a large earthquake has occurred. At stations more than 1 km away from the Hyogo-ken Nanbu earthquake fault zone, the leading shear wave polarization directions (LSPD) are found to be parallel to the axis of the regional maximum horizontal compressional stress (E-W), suggesting that cracks caused by regional tectonic stress exist in the area. However, at stations within 500 m of the earthquake fault zones, the LSPDs are parallel to the fault strikes (N45ø-50øE). This suggests that new fractures were produced parallel to the faults by shear faulting of the Hyogo-ken Nanbu earthquake and resulted in S wave splitting along the earthquake fault zone. Nevertheless, shear fault origin anisotropy was not evident at stations on the active faults which ruptured in 1596. This implies that healing processes have already closed the fractures produced by shear faulting in 1596. Therefore we can expect that S wave splitting can be a useful tool for monitoring healing processes of active faults.
Hepatitis B immunoglobulin (HBIg) and lamivudine combination has been accepted as the best way to control hepatitis B recurrence after liver transplantation. However, the optimal dose of HBIg and the target titer of hepatitis B surface antibody (HBsAb) remain unclear. We report our satisfactory experience with high-dose HBIg in the early period followed by low-dose HBIg with lamivudine. Subjects comprised five patients with fulminant hepatitis (FH) and 18 patients with liver cirrhosis (LC) who underwent liver transplantation. HBIg at a dosage of 200 IU/kg per day was administered for one week postoperatively. Thereafter, HBIg was administered only for HBsAb titer <100 IU/L. After six months, HBIg was withdrawn in FH and administered in LC only for HBsAb titer <10 IU/L. Lamivudine was administered to two FH and all LC cases. Although two patients with LC showed transient hepatitis B surface antigen (HBsAg) recurrence, all patients remained HBsAg-negative at the final follow-up date. This method allows reliable and cost-effective control of hepatitis B recurrence.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.